BIOMAT Database Logo BIOMAT Database Logo

[Antibacterial activities of cefmenoxime against recent fresh clinical isolates from patients in sinusitis]. 1995

N Yokota, and M Koguchi, and Y Suzuki, and S Fukayama, and R Ishihara, and K Deguchi, and S Oda, and S Tanaka, and Y Nakane, and T Fukumoto
Section of Studies, Tokyo Clinical Research Center.

In order to evaluate antimicrobial activity of cefmenoxime (CMX), minimum inhibitory concentrations (MICs) of CMX and control drugs were determined against clinical isolates from patients of sinusitis that were obtained in our laboratory from October of 1993 to March of 1994. The results are summarized as follows; 1. CMX showed strong antimicrobial activities against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella subgenus Branhamella catarrhalis that were 3 major aerobic bacteria from sinusitis. Antimicrobial activities of CMX against benzylpenicillin (PCG)-insensitive S. pneumoniae (PISP) and PCG-resistant S. pneumoniae (PRSP) were stronger than those of ampicillin (ABPC), and these strong activities suggested that CMX might have strong antimicrobial activities against beta-lactamase producing H. influenzae and M. (B.) catarrhalis. 2. Antimicrobial activities of CMX against microaerophiles, Streptococcus constellatus, Streptococcus intermedius and Gemella morbillorum and against Peptostreptococcus spp., from chronic sinusitis and odontogenic maxillary sinusitis, were stronger than those of most of the control drugs. 3. The MIC90's of CMX against isolates from patients of sinusitis were < or = 0.025-0.39 micrograms/ml. These values were lower than transitional concentrations in mucous membrane of maxillary sinus obtained when "1% CMX nasal solution" was used with nebulizer. It appears likely that sufficient concentrations exceeding MICs against main organisms would be obtained by nebulizer treatment using CMX nasal solution.

UI MeSH Term Description Entries
D001936 Moraxella catarrhalis Gram-negative aerobic cocci of low virulence that colonize the nasopharynx and occasionally cause MENINGITIS; BACTEREMIA; EMPYEMA; PERICARDITIS; and PNEUMONIA. Branhamella catarrhalis,Mikrokkokus catarrhalis,Moraxella (Branhamella) catarrhalis
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D006193 Haemophilus influenzae A species of HAEMOPHILUS found on the mucous membranes of humans and a variety of animals. The species is further divided into biotypes I through VIII. Bacterium influenzae,Coccobacillus pfeifferi,Haemophilus meningitidis,Hemophilus influenzae,Influenza-bacillus,Mycobacterium influenzae
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012852 Sinusitis Inflammation of the NASAL MUCOSA in one or more of the PARANASAL SINUSES. Sinus Infections,Infection, Sinus,Infections, Sinus,Sinus Infection,Sinusitides
D013296 Streptococcus pneumoniae A gram-positive organism found in the upper respiratory tract, inflammatory exudates, and various body fluids of normal and/or diseased humans and, rarely, domestic animals. Diplococcus pneumoniae,Pneumococcus
D015281 Cefmenoxime A cephalosporin antibiotic that is administered intravenously or intramuscularly. It is active against most common gram-positive and gram-negative microorganisms, is a potent inhibitor of Enterobacteriaceae, and is highly resistant to hydrolysis by beta-lactamases. The drug has a high rate of efficacy in many types of infection and to date no severe side effects have been noted. Abbott-50192,Cefmax,Cefmenoxime Hydrochloride,Cefmenoxime Hydrochloride (2:1),SCE-1365,Abbott 50192,Abbott50192,Hydrochloride, Cefmenoxime,SCE 1365,SCE1365

Related Publications

N Yokota, and M Koguchi, and Y Suzuki, and S Fukayama, and R Ishihara, and K Deguchi, and S Oda, and S Tanaka, and Y Nakane, and T Fukumoto
[Antibacterial activity of cefmenoxime against clinical isolates. Comparative study].
January 1985, The Japanese journal of antibiotics,
N Yokota, and M Koguchi, and Y Suzuki, and S Fukayama, and R Ishihara, and K Deguchi, and S Oda, and S Tanaka, and Y Nakane, and T Fukumoto
[Antibacterial activities of piperacillin in several fresh clinical isolates].
August 2000, The Japanese journal of antibiotics,
N Yokota, and M Koguchi, and Y Suzuki, and S Fukayama, and R Ishihara, and K Deguchi, and S Oda, and S Tanaka, and Y Nakane, and T Fukumoto
[Antibacterial activity of tosufloxacin against fresh clinical isolates].
March 1994, The Japanese journal of antibiotics,
N Yokota, and M Koguchi, and Y Suzuki, and S Fukayama, and R Ishihara, and K Deguchi, and S Oda, and S Tanaka, and Y Nakane, and T Fukumoto
[Antibacterial activities of fosfomycin against several fresh clinical isolates--comparison of the test methods for antibacterial activity].
December 2002, The Japanese journal of antibiotics,
N Yokota, and M Koguchi, and Y Suzuki, and S Fukayama, and R Ishihara, and K Deguchi, and S Oda, and S Tanaka, and Y Nakane, and T Fukumoto
Recent trends in clinical isolates from paranasal sinusitis.
January 1996, Acta oto-laryngologica. Supplementum,
N Yokota, and M Koguchi, and Y Suzuki, and S Fukayama, and R Ishihara, and K Deguchi, and S Oda, and S Tanaka, and Y Nakane, and T Fukumoto
[Antibacterial activity of biapenem against recent clinical isolates].
April 2003, The Japanese journal of antibiotics,
N Yokota, and M Koguchi, and Y Suzuki, and S Fukayama, and R Ishihara, and K Deguchi, and S Oda, and S Tanaka, and Y Nakane, and T Fukumoto
[In vitro antibacterial activities of carbapenems against clinical isolates].
November 1999, The Japanese journal of antibiotics,
N Yokota, and M Koguchi, and Y Suzuki, and S Fukayama, and R Ishihara, and K Deguchi, and S Oda, and S Tanaka, and Y Nakane, and T Fukumoto
[Antibacterial activity of gatifloxacin against various fresh clinical isolates in 2002].
December 2002, The Japanese journal of antibiotics,
N Yokota, and M Koguchi, and Y Suzuki, and S Fukayama, and R Ishihara, and K Deguchi, and S Oda, and S Tanaka, and Y Nakane, and T Fukumoto
[In vitro antibacterial activities of cefteram and other beta-lactam agents against recent clinical isolates].
January 1998, The Japanese journal of antibiotics,
N Yokota, and M Koguchi, and Y Suzuki, and S Fukayama, and R Ishihara, and K Deguchi, and S Oda, and S Tanaka, and Y Nakane, and T Fukumoto
[Antimicrobial activities of cefminox against recent clinical isolates].
June 1993, The Japanese journal of antibiotics,
Copied contents to your clipboard!